233 related articles for article (PubMed ID: 7581148)
1. In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation.
Fegan C; Thomas H; Bailey-Wood R; Coleman S; Phillips S; Hoy T; Whittaker JA
Bone Marrow Transplant; 1995 Aug; 16(2):277-81. PubMed ID: 7581148
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation.
Neubauer MA; Benyunes MC; Thompson JA; Bensinger WI; Lindgren CG; Buckner CD; Fefer A
Bone Marrow Transplant; 1994 Mar; 13(3):311-6. PubMed ID: 7911048
[TBL] [Abstract][Full Text] [Related]
3. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells in peripheral blood after autologous bone marrow transplantation: a combined phenotypic and functional study.
Jorgensen H; Hokland P; Jensen T; Basse P; Hokland M
Nat Immun; 1995; 14(3):164-72. PubMed ID: 8832900
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms.
Long GS; Cramer DV; Harnaha JB; Hiserodt JC
Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956
[TBL] [Abstract][Full Text] [Related]
7. Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT).
Gratwohl A; Passweg J; Baldomero H; Hermans J
Bone Marrow Transplant; 1999 Aug; 24(3):231-45. PubMed ID: 10456992
[TBL] [Abstract][Full Text] [Related]
8. Blood and marrow transplantation activity in Europe 1996. European Group for Blood and Marrow Transplantation (EBMT).
Gratwohl A; Passweg J; Baldomero H; Hermans J
Bone Marrow Transplant; 1998 Aug; 22(3):227-40. PubMed ID: 9720735
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation.
Arbour S; Toupin S; Bélanger R; Gyger M; Hallé JP; Perreault C; Roy DC
Bone Marrow Transplant; 1996 Mar; 17(3):315-22. PubMed ID: 8704680
[TBL] [Abstract][Full Text] [Related]
10. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
[TBL] [Abstract][Full Text] [Related]
11. Immune reconstitution after purified autologous and allogeneic blood stem cell transplantation compared with unmanipulated bone marrow transplantation in children.
Schwinger W; Weber-Mzell D; Zois B; Rojacher T; Benesch M; Lackner H; Dornbusch HJ; Sovinz P; Moser A; Lanzer G; Schauenstein K; Ofner P; Handgretinger R; Urban C
Br J Haematol; 2006 Oct; 135(1):76-84. PubMed ID: 16925797
[TBL] [Abstract][Full Text] [Related]
12. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution.
Guillaume T; Sekhavat M; Rubinstein DB; Hamdan O; Leblanc P; Symann ML
Cancer Res; 1994 Jul; 54(14):3800-7. PubMed ID: 7913409
[TBL] [Abstract][Full Text] [Related]
13. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
[TBL] [Abstract][Full Text] [Related]
14. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation.
Roberts MM; To LB; Gillis D; Mundy J; Rawling C; Ng K; Juttner CA
Bone Marrow Transplant; 1993 Nov; 12(5):469-75. PubMed ID: 7905331
[TBL] [Abstract][Full Text] [Related]
15. [Reconstitution of peripheral blood lymphocytes in patients treated with bone marrow transplantation: comparison between allogeneic and autologous transplantation].
Parra C; Roldán E; Rodríguez C; Pérez de Oteyza J; Oteho E; López J; Maldonado MS; García Laraña J; Muñoz A; Odriozola J; Brieva JA
Med Clin (Barc); 1999 Jun; 113(1):1-5. PubMed ID: 10422068
[TBL] [Abstract][Full Text] [Related]
16. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow.
Elfenbein GJ; Sackstein R
Exp Hematol; 2004 Apr; 32(4):327-39. PubMed ID: 15050742
[TBL] [Abstract][Full Text] [Related]
17. Indications and donor source of hematopoietic stem cell transplants in Europe 1993: report from the European Group for Blood and Marrow Transplantation (EBMT).
Gratwohl A; Hermans J
Clin Transplant; 1995 Oct; 9(5):355-63. PubMed ID: 8541627
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
Dean R; Masci P; Pohlman B; Andresen S; Serafino S; Sobecks R; Kuczkowski E; Curtis J; Maciejewski J; Rybicki L; Kalaycio M; Hsi E; Theil K; Bolwell BJ
Bone Marrow Transplant; 2005 Dec; 36(12):1049-52. PubMed ID: 16247431
[TBL] [Abstract][Full Text] [Related]
19. Effect of GVHD on the recovery of NK cell activity and LAK precursors following BMT.
Keever CA; Klein J; Leong N; Copelan EA; Avalos BR; Kapoor N; Cunningham I; Tutschka PJ
Bone Marrow Transplant; 1993 Sep; 12(3):289-95. PubMed ID: 8241989
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
